Opus Genetics Says Last Patient Enrolled In Registrational Phase 3 Clinical Trial Evaluating OPGx-LCA5, Investigational Gene Therapy For LCA5-Associated Inherited Retinal Disease
Topline six-month efficacy data expected by end of 2027Phase 3 study follows FDA alignment on registrational trial design through Rare Disease Evidence Principles (RDEP) programOpus Genetics may submit a BLA based on
Opus Genetics finished signing up all the patients they need to test a new gene therapy medicine for a rare eye disease. They'll know if it works by the end of 2027, which is an important step toward possibly selling the medicine.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.